Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors

NCT ID: NCT02209701

Last Updated: 2014-08-06

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1999-12-31

Brief Summary

Study to determine the steady-state pharmacokinetics and urinary excretion of porfiromycin and major metabolites in head and neck cancer and other cancer patients with solid tumors who receive radiation therapy.

Conditions

Head and Neck Neoplasms

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Porfiromycin

Group Type: EXPERIMENTAL

Porfiromycin

Intervention Type: DRUG

Interventions

Porfiromycin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with histologically proven advanced head and neck cancer or other solid tumors undergoing radiation therapy
• Patients with prior chemotherapy will be considered if chemotherapy occurred more than 30 days prior to this study
• Patients must be receiving concomitant radiotherapy (RT)
• Performance status of ≥ 70% on the Karnofsky performance scale (KPS)
• Must be ≥ 18 years of age
• Expected survival of at least three months
• Written informed consent

Exclusion Criteria

• Patients who meet any of the following clinical laboratory criteria:

• Granulocyte count of < 2000/mm**3
• Platelets < 75,000/mm**3
• Serum creatinine > 1.5 times the upper limit of normal
• Bilirubin > 1.5 times the upper limit of normal
• Prothrombin time and partial thromboplastin time > 1.5 times the upper limit of normal
• Women who are pregnant
• Men and women of child-bearing potential who are unwilling to utilize a medically acceptable method of contraception
• Patients who have any known bleeding disorder at the discretion of the investigator
• Presence of any other life-threatening illness, such as unstable angina, severe oxygen dependent chronic obstructive pulmonary disease, or unstable liver or renal disease
• Treatment with granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor or Interleukin-1l within 30 days prior to the start of RT
• Patients who have had prior exposure to mitomycin C or porfiromycin

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

1164.3

Identifier Type: -

Identifier Source: org_study_id